High‐resolution HLA sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2

Abstract

AbstractNarcolepsy is a sleep disorder caused by an apparent degeneration of orexin/hypocretin neurons in the lateral hypothalamic area and a subsequent decrease in orexin/hypocretin levels in the cerebrospinal fluid. Narcolepsy is classified into type 1 (NT1) and type 2 (NT2). While genetic associations in the human leukocyte antigen (HLA) region and candidate autoantibodies have been investigated in NT1 to imply an autoimmune origin, less is known about the pathogenesis in NT2. Twenty‐six NT1 and 15 NT2 patients were included, together with control groups of 24 idiopathic hypersomnia (IH) patients and 778 general population participants. High‐resolution sequencing was used to determine the alleles, the extended haplotypes, and the genotypes of HLA‐DRB3, ‐DRB4, ‐DRB5, ‐DRB1, ‐DQA1, ‐DQB1, ‐DPA1, and ‐DPB1. Radiobinding assay was used to determine autoantibodies against hypocretin receptor 2 (anti‐HCRTR2 autoantibodies). NT1 was associated with HLA‐DRB5*01:01:01, ‐DRB1*15:01:01, ‐DQA1*01:02:01, ‐DQB1*06:02:01, ‐DRB5*01:01:01, ‐DRB1*15:01:01, ‐DQA1*01:02:01, ‐DQB1*06:02:01 (odds ratio [OR]: 9.15; p = 8.31 × 10−4) and HLA‐DRB5*01:01:01, ‐DRB1*15:01:01, ‐DQA1*01:02:01, ‐DQB1*06:02:01, ‐DRB4*01:03:01, ‐DRB1*04:01:01, ‐DQA1*03:02//03:03:01, ‐DQB1*03:01:01 (OR: 23.61; p = 1.58 × 10−4) genotypes. Lower orexin/hypocretin levels were reported in the NT2 subgroup (n = 5) that was associated with the extended HLA‐DQB1*06:02:01 haplotype (p = .001). Anti‐HCRTR2 autoantibody levels were not different between study groups (p = .8524). We confirmed the previous association of NT1 with HLA‐DQB1*06:02:01 extended genotypes. A subgroup of NT2 patients with intermediate orexin/hypocretin levels and association with HLA‐DQB1*06:02:01 was identified, indicating a possible overlap between the two distinct narcolepsy subtypes, NT1 and NT2. Low anti‐HCRTR2 autoantibody levels suggest that these receptors might not function as autoimmune targets in either NT1 or NT2.